Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ.
Jacobson PB, et al. Among authors: opgenorth tj.
J Pharmacol Exp Ther. 2005 Jul;314(1):191-200. doi: 10.1124/jpet.104.081257. Epub 2005 Mar 22.
J Pharmacol Exp Ther. 2005.
PMID: 15784656